Abstract:Objective: The study aims to investigate the role of dynamic [18F]FDG PET/CT imaging by high-sensitivity PET/CT scanner for assessing patients with locally advanced non-small cell lung cancer (LA-NSCLC) who undergo induction immuno-chemotherapy, followed by concurrent hypo-fractionated chemoradiotherapy (hypo-CCRT) and consolidative immunotherapy. Methods: Patients with unresectable LA-NSCLC are prospectively recruited. Dynamic [18F]FDG PET/CT scans are conducted at four timepoints: before treatment (Baseline), after induction immuno-chemotherapy (Post-IC), during hypo-CCRT (Mid-hypo-CCRT) and after hypo-CCRT (Post-hypo-CCRT). The primary lung tumors (PTs) are manually delineated, and the metabolic features, including the Patlak-Ki (Ki), maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been evaluated. The expressions of CD3, CD8, CD68, CD163, CD34 and Ki67 in primary lung tumors at baseline are assayed by immunohistochemistry. The levels of blood lymphocytes at four timepoints are analyzed with flow cytometry. Results: Fifteen LA-NSCLC patients are enrolled between December 2020 and December 2022. Baseline Ki of primary tumor yields the highest AUC values of 0.722 and 0.796 for predicting disease progression and patient death, respectively. Patients are classified into the High FDG Ki group (n = 8, Ki > 2.779 ml/min/100 g) and the Low FDG Ki group (n = 7, Ki ≤ 2.779 ml/min/100 g). The High FDG Ki group presents better progression-free survival (P = 0.01) and overall survival (P = 0.025). The High FDG Ki group exhibits more significant reductions in Ki after hypo-CCRT compared to the Low FDG Ki group. Patients with a reduction in Ki > 73.1% exhibit better progression-free survival than those with a reduction ≤ 73.1% in Ki (median: not reached vs. 7.33 months, P = 0.12). The levels of CD3+ T cells (P = 0.003), CD8+ T cells (P = 0.002), CD68+ macrophages (P = 0.071) and CD163+ macrophages (P = 0.012) in primary tumor tissues are higher in the High FDG Ki group. The High FDG Ki group has higher CD3+CD8+ lymphocytes in blood at baseline (P = 0.108), post-IC (P = 0.023) and post-hypo-CCRT (P = 0.041) than the Low FDG Ki group. Conclusions: The metabolic features in the High FDG Ki group significantly decrease during the treatment, particularly after induction immuno-chemotherapy. The Ki value of primary tumor shows significant relationship with the treatment response and survival in LA-NSCLC patients by the combined immuno-chemoradiotherapy regimen. Trial registration: ClinicalTrials.gov. NCT04654234. Registered 4 December 2020.

Abnormal Brain Glucose Metabolism Patterns in Patients with Advanced Non-Small-cell Lung Cancer after Chemotherapy：a Retrospective PET Study.

Abnormal Brain Glucose Metabolism Patterns in Patients with Advanced Non-Small-Cell Lung Cancer after Chemotherapy:A Retrospective PET Study

Changes of Brain Glucose Metabolism in the Pretreatment Patients with Non-Small Cell Lung Cancer: A Retrospective PET/CT Study.

18F-FDG PET/CT for the Early Prediction of the Response Rate and Survival of Patients with Recurrent or Metastatic Breast Cancer.

Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism.

The Preliminary Study of Brain Glucose Metabolism Changes in Patients with Lung Cancer of Different Histological Types

18 F-FDG PET/CT for Evaluation of Metastases in Nonsmall Cell Lung Cancer on the Efficacy of Immunotherapy.

Construction of an individualized brain metabolic network in patients with advanced non-small cell lung cancer by the Kullback-Leibler divergence-based similarity method: A study based on 18F-fluorodeoxyglucose positron emission tomography

Pretreatment Metabolic Parameters Measured By F-18-Fdg-Pet To Predict The Outcome Of First-Line Chemotherapy In Extensive-Stage Small-Cell Lung Cancer

Inferior Glucose Metabolism and Chemosensitivity of Post-Radiotherapy Local Recurrence in Comparison with Distant Metastases As Assessed by Serial 18F-FDG PET/CT Imaging.

Evaluation of brain metabolism using F18-FDG PET/CT imaging in patients diagnosed with lung cancer

Inferior Glucose Metabolism And Chemosensitivity Of Post-Radiotherapy Local Recurrence In Comparison With Distant Metastases As Assessed By Sequential F-18-Fdg Pet/Ct Imaging

Brain glucose metabolism on [18F]-FDG PET/CT: a dynamic biomarker predicting depression and anxiety in cancer patients

Early Change In Metabolic Tumor Heterogeneity During Chemoradiotherapy And Its Prognostic Value For Patients With Locally Advanced Non-Small Cell Lung Cancer

Kinetic metrics changes of FDG in key organs after chemo-immunotherapy in patients with locally advanced non-small cell lung cancer identified by total-body PET/CT dynamic imaging

Study on Neurologic and Cognitive Dysfunction in Breast Cancer Patients Undergoing Chemotherapy with Resting State Fmri

Differences In Glucose Metabolism And Chemosensitivity Between Post-Radiotherapy Local Recurrence And Distant Metastases

Predictive Value of Metabolic Parameters Derived from Preoperative 18F-FDG Positron Emission Tomography/computed Tomography for Brain Metastases in Patients with Surgically Resected Non-Small Cell Lung Cancer.

Study on Glucose Metabolic Rate in Non-small Cell Lung Cancer Patients with Blood Stasis Syndrome and Non-Blood Stasis Syndrome

Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen